Christoph Brackmann
Fortuna: 3 M $ al 31/07/2026
Fortuna: 3 M $ al 31/07/2026
Mr. Christoph Brackmann is a Chief Financial Officer at NovoCure Ltd. Mr. Brackmann was previously employed as a Senior Vice President-Finance by Moderna, Inc. and a Global Head-Investor Relations by Shire Plc.
He received his undergraduate degree from the University of Mannheim and an MBA from SDA Bocconi School of Management.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
NOVOCURE LTD. 0,16 % | 06/04/2026 | 188.144 ( 0,16 % ) | 3 M $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| NOVOCURE LIMITED | Director Financiero/CFO | 01/01/2025 |
| Empresas | Cargo | Fin |
|---|---|---|
| MODERNA, INC. | Corporate Officer/Principal | - |
| SHIRE | Public Communications Contact | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
University of Mannheim
University of Mannheim Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
NovoCure Ltd.
NovoCure Ltd. Medical SpecialtiesHealth Technology Operates as a commercial-stage oncology company | Health Technology |
SDA Bocconi School of Management
SDA Bocconi School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Moderna, Inc.
Moderna, Inc. BiotechnologyHealth Technology Researches, develops, manufactures and commercializes mRNA-based respiratory & other virus vaccines, oncology and rare disease therapeutics | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.